

## The Genetic Basis of Thyroid Function: Novel Findings and New Approaches

Aleksander Kuś,<sup>1,2,3</sup> Loyal Chaker,<sup>1,2</sup> Alexander Teumer,<sup>4,5</sup> Robin P. Peeters,<sup>1,2</sup> and Marco Medici<sup>1,2,6</sup>

<sup>1</sup>Department of Internal Medicine, Academic Center for Thyroid Diseases, Erasmus Medical Center, Rotterdam 3015 GE, The Netherlands; <sup>2</sup>Department of Epidemiology, Erasmus Medical Center, Rotterdam 3015 GE, The Netherlands; <sup>3</sup>Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw 02-097, Poland; <sup>4</sup>Institute for Community Medicine, University Medicine Greifswald, Greifswald 17475, Germany; <sup>5</sup>DZHK (German Center for Cardiovascular Research), partner site Greifswald, Greifswald 17475, Germany; <sup>6</sup>Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen 6525 GA, The Netherlands.

**ORCID numbers:** 0000-0001-5422-6900 (A. Kuś); 0000-0002-8309-094X (A. Teumer); 0000-0002-7271-7858 (M. Medici).

**Context:** Genetic factors are major determinants of thyroid function. Over the last two decades, multiple genetic variants have been associated with variations in normal range thyroid function tests. Most recently, a large-scale genome-wide association study (GWAS) doubled the number of known variants associated with normal range thyrotropin (TSH) and free thyroxine (FT4) levels.

**Evidence Acquisition:** This review summarizes the results of genetic association studies on normal range thyroid function and explores how these genetic variants can be used in future studies to improve our understanding of thyroid hormone regulation and disease.

**Evidence Synthesis:** Serum TSH and FT4 levels are determined by multiple genetic variants on virtually all levels of the hypothalamus-pituitary-thyroid (HPT) axis. Functional follow-up studies on top of GWAS hits has the potential to discover new key players in thyroid hormone regulation, as exemplified by the identification of the thyroid hormone transporter SLC17A4 and the metabolizing enzyme AADAT. Translational studies may use these genetic variants to investigate causal associations between thyroid function and various outcomes in Mendelian Randomization (MR) studies, to identify individuals with an increased risk of thyroid dysfunction, and to predict the individual HPT axis setpoint.

**Conclusions:** Recent genetic studies have greatly improved our understanding of the genetic basis of thyroid function, and have revealed novel pathways involved in its regulation. In addition, these findings have paved the way for various lines of research that can improve our understanding of thyroid hormone regulation and thyroid diseases, as well as the potential use of these markers in future clinical practice. (*J Clin Endocrinol Metab* 105: 1–15, 2020)

**Key Words:** thyroid, TSH, FT4, genetics, single nucleotide polymorphism, genome-wide association study

**T**hyroid diseases are common and have a negative impact on multiple health outcomes (1). Large

observational and population-based studies showed that even variation in thyroid function within the reference range is associated with adverse clinical outcomes, such as atherosclerotic cardiovascular disease (2), stroke (3), atrial fibrillation (4), type 2 diabetes (5), metabolic syndrome (6), fracture risk (7), dementia (8), depression (9), increased risk of thyroid cancer in

ISSN Print 0021-972X ISSN Online 1945-7197

Printed in USA

Published by Oxford University Press on behalf of the Endocrine Society 2020

Received 1 August 2019. Accepted 6 January 2020.

First Published Online 9 April 2020.


Corrected and Typeset 9 April 2020.

patients with thyroid nodules (10–12), and mortality (13). Therefore, it is essential to understand the mechanisms underlying these variations in thyroid function. In healthy persons, serum TSH and thyroid hormone (TH) levels show substantial interindividual variation, while the intraindividual variation lies within a much narrower range (14). The observed interindividual variation can be partially attributed to differences in individual characteristics (eg, age and BMI) and exposure to environmental factors (eg, iodine intake) (15). However, studies in mono- and dizygotic twins demonstrated that genetic factors are major determinants of thyroid function, responsible for 45–65% of the interindividual variation in TSH and TH levels (16). It has been suggested that besides rare variants with large effects (mutations), the overall effect of the genetic factors on an individual’s TSH and TH levels is determined by multiple common variants (polymorphisms) with small effect sizes (17, 18). Over the last two decades, several genetic variants have been associated with thyroid function in candidate gene studies, while more recently, many more variants were identified in genome-wide association studies (GWAS) (17, 18). The largest GWAS on thyroid function to date has been recently performed within the ThyroidOmics Consortium in 72 000 individuals and greatly increased the number of associated genetic variants (19). In the current review, we will discuss the knowns and unknowns of the genetic factors involved in the regulation of thyroid function, with a special emphasis on the most recently identified variants. Moreover, we will discuss several approaches in which these novel data can be used to improve our understanding of thyroid


physiology and disease, as well as the potential use of these markers in future clinical practice.

### Genetic Determinants of Thyroid Function

Early work on genetic determinants of thyroid function often involved candidate gene studies that analyzed a limited number of genetic variants located within specific genes selected based on their known function. Later on, GWAS allowed researchers to investigate the association of approximately 1 000 000 independent genetic variants across the entire genome with the trait of interest, using a hypothesis-free approach (20). To avoid false-positive results due to multiple testing, an adjusted *P*-value threshold ( $P < 5 \times 10^{-8}$ ) is used to declare statistical significance in GWAS (21). Large sample sizes are therefore required to ensure sufficient power. The first GWAS on TSH levels, performed in 2008 by Arnaud-Lopez et al in 4300 Sardinians, identified one genome-wide significant locus (ie, *Phosphodiesterase 8B [PDE8B]*) (22). This list was further extended by several larger GWAS performed by Gudmundsson et al (23), Porcu et al (24), and others (25–31). As illustrated in Figure 1, the increasing number of subjects included in every next GWAS led to a steep increase in newly identified variants. The most recent GWAS performed by the ThyroidOmics Consortium ([www.thyroidomics.com](http://www.thyroidomics.com)) identified 19 novel loci associated with normal range TSH levels and 16 novel loci associated with normal range free thyroxine (FT4) levels, leading to a total of 42 and 21 known and novel associated loci for these two



**Figure 1. Identified serum TSH and/or FT4 associated loci over time, using different study techniques.** Variants found to be significant in candidate gene studies were included when associations were replicated in at least one independent population ( $N > 500$ ) or in case of in vitro evidence for functionality. Abbreviations: GWAS, genome-wide association study; N, number of subjects analyzed in the study; WGS, whole-genome sequencing.



**Figure 2. Manhattan plots of the GWAS meta-analysis results for TSH and FT4 contrasted with each other.** Single nucleotide polymorphisms (SNPs) are plotted on the x-axis according to their position on each chromosome with  $-\log_{10}(p\text{-value})$  on the y-axis. The upper solid horizontal line indicates the threshold for genome-wide significance, ie,  $5 \times 10^{-8}$ . Genomic loci previously known to contain trait-associated variants are colored in black, new loci in gray. Adapted from Teumer et al (19).

traits (Figures 1 and 2) (19), which we briefly discuss in this section. As variants associated with hypothyroidism and hyperthyroidism are not in the scope of this review, we refer to previous comprehensive reviews (17, 32, 33).

### Established players

The results of genetic association studies demonstrate that TSH and TH levels are determined by variants in genes involved in the regulation of thyroid function on virtually all levels of the hypothalamus-pituitary-thyroid (HPT) axis and peripheral thyroid hormone regulation (17, 18). Based on their function, these genes can be classified into several groups, which often tend to predominantly determine either TSH or TH levels, as presented in Table 1. We highlight typical examples for each of these groups below.

**Genes encoding proteins implicated in development and function of the HPT axis.** Several variants associated with TSH and/or TH levels localize within genes encoding proteins implicated in the development and function of the HPT axis. These include important transcription factors as well as growth factors and their binding proteins (Table 1).

**Transcription factors.** The first group includes variants in genes encoding transcription factors expressed in the HPT axis, which are often associated with both TSH and TH levels (Table 1). The associated biochemical fingerprint depends on whether these factors primarily contribute to the development and function of the thyroid or pituitary. For example, *LIM homeobox 3* (*LHX3*) encodes a transcription factor involved in pituitary development. *LHX3* variants have been predominantly associated with lower FT4 levels, with either no effects on TSH levels (16) or lower TSH levels (21), which is indeed the hallmark of a central hypothyroidism-like effect. This is supported by the observation that inactivating mutations of the *LHX3* gene can lead to central congenital hypothyroidism accompanied by growth hormone and gonadotropin deficiency (42).

On the other hand, variants of genes encoding transcription factors primarily involved in thyroid development and function tend to be associated with FT4 and TSH levels in the opposite direction, as illustrated by variants in the *GLIS family zinc finger 3* (*GLIS3*) gene. *GLIS3* encodes a zinc finger transcription factor, acting as both repressor and activator of gene transcription

**Table 1. Genetic loci associated with variation in normal range TSH and FT4 levels classified by their function in the hypothalamus–pituitary–thyroid axis and peripheral thyroid hormone regulation.**

| Locus   | Annotated gene | Gene full name  | Function in the HPT axis   | Associated trait | Direction (when affecting both TSH and FT4) | References               |
|---|----------------|---|--|------------------|---|--------------------------|
| <b>Genes encoding proteins implicated in development and function of the HPT axis</b> |                |   |  |                  |   |                          |
| <b>Transcription factors</b>  |                |   |  |                  |   |                          |
| 9q22  | FOXE1          | Forkhead box E1   | Main mediator of TSH-regulated expression of thyroid-specific genes  | FT4/TSH          | Same  | (19, 23, 24, 28, 30, 34) |
| 9q34  | LHX3           | LIM homeobox 3  | Transcription factor required for pituitary development  | FT4/(TSH)        | Same  | (19, 24, 34)             |
| 9p24  | GLIS3          | GLIS family zinc finger 3   | Transcription factor implicated in thyroid development   | TSH/FT4          | Opposite                                    | (19, 24)                 |
| 1p31  | NFIA           | Nuclear factor I A  | Interacts with thyroid transcription factor 1, which is essential for the expression of thyroid-specific genes | TSH/(FT4)        | Opposite                                    | (19, 23, 24)             |
| 14q13   | TFPI/MBIP      | NK2 homeobox 1 (thyroid transcription factor 1)/ MAP3K12 binding inhibitory protein 1       | Transcription factor crucial for thyroglobulin expression and thyroid differentiation (TTF1)                   | TSH/(FT4)        | Opposite                                    | (19, 24, 34)             |
| 17q23   | SOX9           | SRY-box 9   | Transcription factor expressed both in the pituitary and thyroid, which interacts with the TH receptor complex | TSH              | NA  | (19, 24)                 |
| 17p11-12  | NCOR1          | Nuclear receptor corepressor 1  | Corepressor involved in mediating TH action  | FT4              | NA  | (19)                     |
| <b>Growth factors and their binding proteins</b>                                      |                |   |  |                  |   |                          |
| 6p12  | VEGFA          | Vascular endothelial growth factor A  | Growth factor implicated in angiogenesis and iodine supply to the thyroid                                      | TSH/(FT4)        | Opposite                                    | (19, 23, 24, 28, 34)     |
| 15q21   | FGF7           | Fibroblast growth factor 7  | Plays a role in the development of the thyroid   | TSH/(FT4)        | Opposite                                    | (19, 23, 24)             |
| 2q35  | IGFBP2/IGFBP5  | Insulin like growth factor binding protein 2 / Insulin like growth factor binding protein 5 | Enhanced production of IGFBP5 is correlated with inhibition of thyroid function                                | TSH/(FT4)        | Opposite                                    | (19, 23, 24, 34)         |
| 3q27  | IGF2BP2        | Insulin like growth factor 2 mRNA binding protein 2   | Regulates translation of IGF2, which may have proliferative effects on follicular thyroid cells                | TSH              | NA  | (19)                     |
| 19p13   | INSR           | Insulin receptor  | Binds insulin, IGF1 and IGF2, which have proliferative effects on follicular thyroid cells                     | TSH              | NA  | (19, 23, 24)             |
| 6q24  | SASH1          | SAM and SH3 domain containing 1   | Downstream target of the insulin/IGF1 signaling pathway  | TSH              | NA  | (19, 24)                 |
| 20p11   | FOXA2          | Forkhead box A2   | Downstream target of the insulin/IGF1 signaling pathway  | TSH              | NA  | (19, 23)                 |

Table 1. Continued

| Locus   | Annotated gene           | Gene full name  | Function in the HPT axis  | Associated trait | Direction (when affecting both TSH and FT4) | References                   |
|---|--------------------------|---|---|------------------|---|------------------------------|
| <b>Genes encoding proteins involved in the TSH receptor signaling cascade</b> |                          |   |   |                  |   |                              |
| 14q31   | <i>TSHR</i>              | <i>Thyroid stimulating hormone receptor</i>   | Stimulates TH synthesis and release in response to TSH  | TSH              | NA  | (19, 35, 36)                 |
| 5q13  | <i>PDE8B</i>             | <i>Phosphodiesterase 8B</i>   | Inactivates cAMP signaling activated by TSHR response to TSH                                  | TSH(FT4)         | Opposite                                    | (19, 22-24, 26, 27, 31, 34)  |
| 6q27  | <i>PDE10A</i>            | <i>Phosphodiesterase 10A</i>  | Inactivates cAMP signaling activated by TSHR response to TSH                                  | TSH              | NA  | (19, 23, 24, 28, 34)         |
| 14q32   | <i>ITPK1</i>             | <i>Inositol-tetrakisphosphate 1-kinase</i>  | Regulates the phosphatidylinositol pathway activated by TSHR response to TSH                  | TSH(FT4)         | Opposite                                    | (19, 23, 24)                 |
| 20q13   | <i>GNAS</i>              | <i>GNAS complex locus</i>   | Stimulates the activity of adenylate cyclase which directly regulates cAMP signaling          | TSH              | NA  | (37)                         |
| <b>Genes encoding proteins directly involved in thyroid hormone synthesis</b> |                          |   |   |                  |   |                              |
| 2p25  | <i>TPO</i>               | <i>Thyroid peroxidase</i>   | Catalyzes the iodination of tyrosine residues and their subsequent coupling to iodothyronines | TSH              | NA  | (23)                         |
| 8q24  | <i>TG</i>                | <i>Thyroglobulin</i>  | Acts as a substrate for the synthesis of T4 and T3  | TSH              | NA  | (19)                         |
| 1p36  | <i>CAPZB</i>             | <i>Capping actin protein of muscle Z-line subunit beta</i>  | Takes part in TSH-induced protrusion of microvilli and filopodia from the thyrocyte surface   | TSH              | NA  | (19, 23, 24, 26, 30, 34)     |
| <b>Genes encoding thyroid hormone transporters</b>                            |                          |   |   |                  |   |                              |
| Xq13  | <i>MCT8 (SLC16A2)</i>    | <i>Monocarboxylate transporter 8 (Solute carrier family 16 member 2)</i>  | TH transporter  | FT4              | NA  | (38)                         |
| 12p12   | <i>OATP1B1 (SLCO1B1)</i> | <i>Solute carrier organic anion transporter family member 1B1</i>   | TH transporter  | FT4              | NA  | (19, 39)                     |
| 6p22  | <i>SLC17A4</i>           | <i>Solute carrier family 17 member 4</i>  | TH transporter  | FT4              | NA  | (19)                         |
| <b>Genes encoding enzymes involved in thyroid hormone metabolism</b>          |                          |   |   |                  |   |                              |
| 1p32  | <i>DIO1</i>              | <i>Iodothyronine deiodinase 1</i>   | Responsible for TH metabolism, mainly the conversion of T4 to T3 and rT3 to T2                | FT4              | NA  | (19, 24, 34, 36, 40, 41)     |
| 14q31   | <i>DIO2</i>              | <i>Iodothyronine deiodinase 2</i>   | Responsible for conversion of T4 to T3 and rT3 to T2  | FT4              | NA  | (19)                         |
| 14q32   | <i>DIO3OS</i>            | <i>DIO3 opposite strand upstream RNA</i>  | Potential regulator of <i>DIO3</i> expression   | FT4              | NA  | (19)                         |
| 4q33  | <i>AADAT</i>             | <i>Aminoacidpate aminotransferase</i>   | TH metabolizing enzyme  | FT4              | NA  | (19, 24, 34)                 |
| <b>Genes with unknown function in the HPT axis</b>                            |                          |   |   |                  |   |                              |
|   |                          | <i>NR3C2, XKR4, ELK3, SIVA1, NKX2.3, DIRC3, VAV3, NRG1, ABO, MIR1179, PRDM11, LPCAT2, NETO1, SYN2, B4GALT6 (SLC25A52), HES1, PSORS1C1, SLC25A37, SULF1, C9orf92, GATA3, PTEN, CADM1, SPATA13, ADCY9, MIR365A, NSF, BCAS3, PRKX, ACOMSD, SOX2-OT, ID4, LOC728012, CA8, NEK6, FNBP4, USP3, SNX29, MCF4R, TM45F4, LOC440389 (MAF), CNTN5</i> |   |                  |   | (19, 23, 24, 26, 28, 30, 34) |

Loci associated in candidate gene studies were included when associations were replicated in at least one independent population ( $N > 500$ ) or in case of in vitro evidence for functionality. Effects on TSH and/or FT4 levels are shown between brackets when they were only significant in secondary analyses (and not in the main GWAS analysis). Abbreviations: TH, thyroid hormone; NA, not applicable.



in the thyroid (43). Animal models and in vitro studies showed that *GLIS3* is essential for proliferation of thyroid follicular cells and synthesis of TH, as it is involved in transcription of the iodide transporters, sodium iodide symporter (*NIS/SLC5A5*) and pendrin (*PDS/SLC26A4*) (44). Mutations in the *GLIS3* gene have been associated with primary congenital hypothyroidism, accompanied by neonatal diabetes (45). Of note, *GLIS3* was the only locus associated with both TSH and FT4 levels at the genome-wide significant level in the most recent GWAS (19), and the same *GLIS3*-rs10814915 allele was associated with higher TSH and lower FT4 levels.

**Growth factors and their binding proteins.** Variants in genes encoding growth factors expressed in the thyroid are also predominantly associated with TSH levels and, to a lesser extent, with FT4 levels in the opposite direction (Table 1). Such biochemical fingerprints were indeed noted for variants in *VEGFA* (encoding vascular endothelial growth factor A) and *FGF7* (encoding fibroblast growth factor 7). *VEGFA* promotes angiogenesis and proper microvasculature development, which is essential for iodine and TSH supply to the thyrocytes (46,47). In turn, *FGF7* plays an important role in thyroid development and promotes thyrocyte proliferation (48). Of note, *FGF7* was also one of the significant hits in the goiter GWAS by Teumer et al (49). Interestingly, the same *FGF7*-rs4338740 allele was associated with both increased thyroid volume in the study by Teumer et al (49) and lower TSH levels in several GWAS (19, 23, 24). These findings are in line with the results of observational studies showing that higher thyroid volume is associated with lower TSH levels in euthyroid adults (50–52) and children (53, 54). These results suggest that variants associated with increased *FGF7* activity result in increased thyroid cell mass and volume, and it appears that for these thyroids lower TSH levels are required to maintain normal FT4 levels.

**Genes encoding proteins involved in the TSH receptor signaling cascade.** Another important group of genetic determinants of thyroid function includes variants in genes encoding the TSH receptor (*TSHR*) and other proteins involved in the cascade, which follows after TSH is bound to the *TSHR*. As can be physiologically expected, such variants primarily affect TSH levels (Table 1), with some also having minor effects on TH levels in the opposite direction. This can be illustrated by variants in the *PDE8B* gene. *PDE8B* encodes a phosphodiesterase, which is highly expressed in the thyroid and responsible for the inactivation of cyclic adenosine monophosphate (cAMP), which is produced after *TSHR* activation. All large GWAS have identified

that several *PDE8B* variants are associated with serum TSH levels, while their association with FT4 levels is much weaker (19,23,24). It is speculated that the identified genetic variants increase *PDE8B* activity, leading to lower cAMP levels. Consequently, a higher TSH level is required to maintain normal FT4 levels.

**Genes encoding TH transporters and enzymes involved in TH metabolism.** In contrast, variants in genes encoding proteins involved in TH transport and metabolism result in altered TH levels without any evident change in TSH levels (Table 1). This can be illustrated by *DIO1* encoding type 1 iodothyronine deiodinase. Several independent *DIO1* variants have been associated with TH levels but not TSH levels in GWAS and candidate gene studies (19, 24, 36, 40, 41). *DIO1* plays an important role in the peripheral conversion of thyroxine (T4) to triiodothyronine (T3) and the degradation of reverse T3 (rT3). Therefore, variants associated with lower *DIO1* activity lead to higher T4 levels and lower T3 levels, resulting in a net euthyroid status, as reflected by the absence of an association with TSH.

The examples above illustrate that the identified effects of many variants fit nicely with the gene's role in TH regulation. In turn, the biochemical fingerprint of variants in genes with a yet unknown role in TH regulation can therefore also be used to provide clues about the role of the associated gene in the HPT axis or peripheral TH regulation. This is illustrated by the recent identification of the roles of aminoacidase aminotransferase (*AADAT*) and solute carrier family 17 member 4 (*SLC17A4*) in TH regulation, which we discuss more extensively below. The exact location of the gene in the HPT axis and their associated effects on TSH and TH levels is also important when considering the use of these variants in Mendelian Randomization and prediction studies, as discussed later in this review.

### Novel players

The most recent GWAS on thyroid function doubled the number of loci associated with TSH and FT4 levels (19). This included novel variants within known thyroid-related genes or related pathways, but also a number of variants within genes without an established role in the regulation of TSH and FT4 levels (Table 1). Functional follow-up studies on two of these genes (*AADAT* and *SLC17A4*) confirmed their role in TH regulation, as discussed below.

**AADAT – a novel thyroid hormone metabolizing enzyme.** GWAS have found that genetic variation in the *AADAT* locus is associated with variation in FT4 levels (19, 24). *AADAT* is highly expressed in multiple

tissues, including the liver, gastrointestinal tract, and kidney (55), but until recently its role in TH regulation remained completely unknown. Given the observed associations with TH levels and the fact that *AADAT* encodes a mitochondrial aminotransferase with broad substrate specificity, Dr Theo Visser postulated that *AADAT* could encode a TH metabolizing enzyme. This was indeed confirmed by in vitro studies, in which cell lysates of human *AADAT* transfected cells were incubated with THs. When compared to empty vector transfected cells, this led to an increased conversion of THs (amongst others, T4 and T3) to their pyruvic acid metabolites (19). Further studies showed that the identified *AADAT* gene variant (rs6854291) was also associated with lower serum T3 levels and a lower T3/T4 ratio (19). These results show that *AADAT* is a TH metabolizing enzyme, which is likely to play a critical role in the rate of TH metabolism.

**SLC17A4 – a novel thyroid hormone transporter.** The most recent GWAS on FT4 levels identified two independent variants within the *SLC17A4* gene (rs9356988 and rs137964359) to be associated with FT4 levels (19). The *SLC17A4* gene encodes an organic anion transporter that is particularly expressed in the liver, kidney, and gastrointestinal tract (56,57). Given its association with TH levels, it was postulated that *SLC17A4* could encode a TH transporter. In vitro studies indeed confirmed that *SLC17A4* is a high-affinity T3 and T4 transporter, with similar properties as monocarboxylate transporter 8 (MCT8), the most specific TH transporter identified to date (19).

**DIO3OS – a potential regulator of *DIO3* expression.** Type 3 deiodinase (*DIO3*) is responsible for the degradation of TH (T4 to rT3 and T3 to T2). In mice, *DIO3* is critical for the maturation and function of the HPT axis, as mice lacking *DIO3* activity develop perinatal thyrotoxicosis followed by mild central hypothyroidism in adulthood (58, 59). Whereas genetic variation in *DIO3* was found not to be associated with TSH and/or TH levels in humans in candidate gene studies (36, 40, 41) or previous GWAS (22–31), two independent variants within the *DIO3* *opposite strand upstream RNA* (*DIO3OS*) gene have been associated with FT4 levels in the most recent GWAS on thyroid function (19). *DIO3* and *DIO3OS* are overlapping genes transcribed in opposite directions (60), and Kester et al demonstrated that *DIO3* and *DIO3OS* are co-expressed in various human cell lines (61). Whereas *DIO3* is an imprinted gene, *DIO3OS* may be involved in maintaining

monoallelic expression of *DIO3* (62, 63), which could explain the observed associations with TH levels. Future studies should clarify whether these variants indeed affect *DIO3* expression.

**Novel variants within thyroid-related genes and known pathways.** Type 2 iodothyronine deiodinase (*DIO2*) is involved in the conversion of T4 to T3 and rT3 to T2. The most frequently tested *DIO2* variants are rs225014 (also known as p.92T > A) and rs12885300 (also known as ORFa-Gly3Asp). *DIO2*-rs12885300 is located in a short open reading frame within the 5'UTR of the *DIO2* gene. This part of the gene is thought to be responsible for the inhibitory effect of the 5'UTR on *DIO2* transcription, which is supported by in vitro analyses showing that the Asp variant is associated with increased gene transcription and *DIO2* activity (64). In line with this finding, Peeters et al showed that this variant is associated with an increased T3/T4 ratio (65). However, this could not be replicated by others (66, 67), while this variant was neither associated with T4 levels in the most recent GWAS (19), suggesting that this variant does not have any substantial effects on circulating T3 and T4 levels, or their ratio.

*DIO2*-rs225014 is a non-synonymous variant resulting in the Thr92Ala substitution, which has been investigated in several in vitro studies (36, 68–70). Initial studies did not find effects of the Ala variant on T4 to T3 conversion in transfected human kidney (HEK) cells and fibroblast-like cells derived from monkey kidney tissue (COS cells) (36, 68). However, Canani et al did show decreased *DIO2* activity in muscle and thyroid samples from patients with type 2 diabetes mellitus who were homozygous for the Ala variant (68). More recently, Castagna et al performed a series of experiments on *DIO2*-rs225014 functionality in mice, amongst others, demonstrating lower T4 to T3 conversion in *DIO2*-92Ala-transfected myoblasts and pituitary cells compared with *DIO2*-92Thr-transfected myoblasts and pituitary cells in *DIO2*-null mice (69). Collectively, these studies provide strong evidence for the functional effects of the *DIO2*-rs225014 variant in multiple cell lines. Despite this, *DIO2*-rs225014 was not associated with serum TSH and/or TH levels in several candidate gene studies (36, 67, 71, 72) and previous GWAS (24, 28, 29). However, the most recent GWAS proved that rs225014 and two other *DIO2* variants (rs150816132 and rs978055, but not rs12885300) are indeed associated with normal-range FT4 levels (19), which clearly demonstrates the advantage of well-powered large-scale studies in identifying variants associated with thyroid

function. Multiple studies investigated the potential clinical implications of the *DIO2*-rs225014 variant, which we will discuss later in this review. Of note, the recent GWAS also provided evidence for other thyroid-related genes (eg, *TSHR*, *TG*, *OATP1B1*) and identified several novel independent variants within the established loci (eg, *PDE8B*, *CAPZB*, *DIO1*) (Table 1).

### Genes of unknown function in thyroid hormone regulation

Finally, a large part of the newly and previously identified loci (eg, *MAF*, *PRDM11*, *DIRC3*, *CA8*, *PRKX*, *XKR4*, and *SNX29*; see Table 1) do not have any known role in TH regulation. These loci form a particularly interesting group for further research, possibly elucidating new pathways in thyroid physiology as illustrated by the successful in vitro studies on *AADAT* and *SLC17A4*. Importantly, GWAS hits do not necessarily always pinpoint causal variants and genes, as the observed association might in some cases result from linkage disequilibrium with other (rare) variants yielding the causal effect (73). For example, the *beta-1,4-galactosyltransferase 6* (*B4GALT6*) variant (rs113107469) identified by Taylor et al (34) is tagging a much rarer and potentially functional variant (rs28933981, minor allele frequency of 0.4%) in the gene encoding transthyretin (*TTR*), resulting in the Thr139Met substitution, which was associated with an increased thyroxine-binding affinity (34). Therefore, follow-up studies for these loci are a key next step to understand the mechanisms underlying the observed associations.

### Implications for Clinical Practice

As reviewed above, many genetic determinants of thyroid function have been identified in the last few years. Here we discuss ways in which these data could serve future clinical practice. In particular, we will discuss


how identified genetic variants could be used to: (1) investigate causal associations between thyroid function and adverse outcomes, (2) predict the individual risk of thyroid dysfunction and its response to treatment, and (3) define the individual HPT axis setpoint.

### Mendelian randomization studies

In the last decade, multiple observational studies have reported associations between minor variations in thyroid function and adverse clinical outcomes (2-9, 13). This has opened up a discussion whether reference ranges for thyroid function tests should be adapted (74, 75). However, observational studies are prone to biases in study design, residual confounding, and reverse causality (76). In most cases, it is therefore unclear whether causal relationships underlie the observed associations. One possible and currently popular approach is to perform a Mendelian Randomization (MR) study. In MR, the effect of an exposure (eg, thyroid function) on an outcome (eg, cardiovascular disease) is evaluated using genetic variants associated with the exposure as the instruments (Figure 3). This concept draws from the fact that genetic variants segregate randomly from parents to offspring, which can be compared to randomization used in clinical trials. As genetic variants can affect an outcome (*via* exposure) but not the other way around, an association between the genetically estimated exposure and outcome can confirm the causality of the observed association. However, this approach requires several assumptions (77, 78). Most importantly, the instruments have to be truly associated with the exposure, and the effect of the instruments on the outcome has to be mediated solely by the exposure. This means that weak and pleiotropic instruments should be avoided since they can strongly bias the causal estimates (79, 80). Another important prerequisite is that a conclusive MR requires appropriate power, which depends on several parameters, including study sample size, magnitude

#### MR – core assumptions

1. The genetic variants used as instruments must be truly associated with the exposure.
2. The genetic variants should only be related to the outcome of interest through the exposure under study.
3. The genetic variants should not be associated with any confounders of the exposure-outcome relationship.



**Figure 3. Core assumptions for Mendelian Randomization (MR) studies.** Arrows indicate the direct effect of one variable on the other, while dashed arrows with a cross indicate that there should be no direct effect of one variable on the other.



of the causal association between the exposure and outcome, and proportion of variance in the exposure explained by the genetic instruments used (81).

Several MR studies have attempted to clarify the causal relationships between minor variation in thyroid function and various outcomes, including cardiovascular disease (82, 83), type 2 diabetes (84), bone mineral density and fracture risk (85), and kidney function (86). However, none of them found evidence for a causal association between thyroid function and the tested outcome. More recently, two MR studies (87, 88) provided evidence for causal effects of minor variation in thyroid function on atrial fibrillation (AF) risk, as they found that genetically-predicted decreased TSH levels, as well as increased FT3:FT4 ratios (but not FT4 levels), were associated with an increased risk of AF (87, 88). While negative results of MR studies could indicate lack of causal effects of thyroid function on tested outcomes, they might also result from insufficient power to detect existing effects. The identification of many novel genetic variants associated with serum TSH and FT4 levels in the most recent GWAS by the ThyroidOmics Consortium will significantly increase the power of future MR studies. However, there are more requirements to ensure a high quality of future MR studies (89). First of all, a good understanding of mechanisms underlying the association between thyroid function and genetic variants used as instruments in MR studies is essential. For example, several *DIO1* variants have been associated with FT4 levels in GWAS. Since *DIO1* is responsible for peripheral conversion of T4 to T3, the higher T4 levels coincide with lower T3 levels, leading to a net euthyroid status, as reflected by the absence of an association with TSH. Consequently, while these variants can be used as instruments for variation in normal-range FT4 levels, they should not be interpreted as being instruments for increased thyroid function, despite their relation with higher FT4 levels. Therefore, a good understanding of the role of identified loci in the HPT axis and their resulting associations with thyroid function tests (Table 1) is a key for an appropriate interpretation of MR study results. Moreover, it is important to remember that thyroid dysfunction is mostly caused by autoimmunity and that autoimmune diseases frequently coincide. For this reason, it is not always clear whether the causal effect of hypothyroidism or hyperthyroidism on an outcome observed in a MR study is attributed solely to thyroid dysfunction or rather to concomitant autoimmune disorders. Furthermore, even the associations with normal range TSH and FT4 levels can reflect either alterations in the HPT axis setpoint or mild (early stage) thyroid

disease. Data from GWAS on (subclinical) hypo/hyperthyroidism (19) and thyroid peroxidase antibody positivity (90) available at the ThyroidOmics Consortium website ([www.thyroidomics.com](http://www.thyroidomics.com); genetic associations section) can be used to distinguish between these two groups.

### Predicting the individual risk of thyroid disease and treatment response

It is an intriguing question as to whether data from large-scale genetic association studies can eventually serve the management of individual patients. In the following sections we discuss the potential role of genetic variations in *DIO2*, as well as the use of genetic risk scores (GRS).

**Type 2 deiodinase.** Approximately 70% of circulating T3 derives from peripheral T4 deiodination catalyzed by *DIO2* (91). As discussed above, *DIO2*-rs225014 has been shown to affect *DIO2* activity in several cell lines (68–70). Several small-scale epidemiological studies have shown associations between this variant and various clinical endpoints, including type 2 diabetes, hypertension, osteoarthritis, bipolar disorder, and others (17, 18, 92). Additionally, it has been hypothesized that, because of impaired T4/T3 conversion, hypothyroid patients harboring the Ala variant may experience a benefit from LT4/LT3 combination therapy. For these reasons, three clinical studies have assessed the potential role of this variant in determining LT4/LT3 combination therapy efficacy. The first study was performed by Appelhof et al (71) in 2005, who did not find effects of the *DIO2*-rs225014 genotype on baseline well-being or appreciation of LT4/LT3 combination therapy in 141 hypothyroid patients ( $P > 0.05$ ). In 2009, Panicker et al (93) performed a retrospective analysis in 552 hypothyroid patients from the Weston Area T4 /T3 Study (WATTS), in which patients on a stable dose of LT4 therapy were previously randomized to either LT4/LT3 combination therapy or the original LT4 monotherapy dose (94). In this study, patients homozygous for the Ala variant had an impaired psychosocial well-being at baseline as assessed by the General Health Questionnaire (GHQ) and showed greater improvement in the GHQ score on LT4/LT3 combination therapy when compared with LT4 monotherapy (by 2.3 GHQ points at 3 months and 1.4 points at 12 months,  $P = 0.03$ ) (93). However, these results were not statistically significant when correcting for multiple testing, whereas significant heterogeneity in baseline psychosocial well-being and improvement on LT4/LT3 combination therapy was observed within the groups of patients stratified by

the *DIO2*-rs225014 genotype (93). No association between the *DIO2*-rs225014 variant and health-related quality of life measured using the RAND36-Item Health Survey (95) was either found in 364 patients on LT4 treatment by Wouters et al (72). More recently, Carle et al (96) performed a small ( $N = 45$ ) prospective double-blind randomized clinical trial in which they found that hypothyroid patients harboring combined *MCT10*-rs17606253 and *DIO2*-rs225014 variants ( $P = 0.009$ ), but not *DIO2*-rs225014 alone ( $P > 0.05$ ), may prefer LT4/LT3 combination treatment. While these results need to be interpreted with caution given the small sample size of the study (96), they may suggest that a combination of multiple variants, rather than *DIO2*-rs225014 alone, may contribute to differences in response to LT4/LT3 combination therapy observed between patients. In summary, while it has been proven that the *DIO2*-rs225014 variant affects *DIO2* function as well as circulating serum T4 levels, it is highly unlikely that this single variant alone is of substantial predictive value in the individual patient. The interindividual differences in response to LT4 monotherapy, as well as LT4/LT3 combination therapy, are more likely to be explained by a combination of multiple variants (common or rare with large individual effects sizes), which should be the scope of future genetic and clinical studies.


**Genetic risk scores.** The most prominent research using GRS comes from the cardiovascular field. For example, using a GRS that combined 50 single nucleotide polymorphisms (SNPs) associated with coronary artery disease (CAD) in GWAS, Khera et al (97) showed that participants with a GRS in the highest quintile had a 91% higher relative risk of incident coronary events compared to those with a GRS in the lowest quintile. A more robust polygenic score was able to identify 8% of population at a greater than threefold increased risk of CAD (98). Given the ongoing identification of novel genetic variants associated with CAD and the continuously decreasing costs of genotyping arrays, implementation of such GRS into everyday clinical practice starts to be considered as a cost-effective method for improving the effectiveness of prevention and treatment for CAD (99, 100).

As GWAS on thyroid function have identified many variants in the last decade (Figure 1), a number of studies have also investigated the use of these variants to identify individuals with increased risk of thyroid dysfunction. In a follow-up analysis for their GWAS on serum TSH and FT4 levels using GRS based on 20 variants associated with normal range TSH levels, Porcu et al (24) showed that the odds of increased TSH levels were 6.65 times greater in individuals with a GRS in

the top quartile compared to individuals in the bottom quartile ( $P = 3.4 \times 10^{-20}$ ). In another study, Schultheiss et al (101) showed that a GRS based on nine variants associated with thyroid peroxidase antibodies (TPOAbs) in a dedicated GWAS (90) can be used to identify individuals with an increased risk of both overt and subclinical hypothyroidism (interquartile odds ratio of 1.89 and 1.80, respectively). Furthermore, the most recent GWAS on thyroid function also showed that a GRS based on variants associated with TSH levels within the normal range strongly correlates with the risk of both (subclinical) hypothyroidism and hyperthyroidism (Figure 4) (19). However, it should be noted that while showing impressive effects at the extremes, the number of subjects carrying extremely low or high GRS was limited, and these markers still have insufficient discriminatory power to be used in clinical practice. Nevertheless, these results illustrate in which ways they could be used to help identify individuals with an increased risk of thyroid dysfunction or personalize the treatment of patients with thyroid disease in the future.

#### Defining the individual HPT axis setpoint

Serum TSH and TH levels in healthy persons show substantial interindividual variation, while the intraindividual variation is much smaller (14). This



**Figure 4. Associations of genetic risk scores with hypothyroidism and hyperthyroidism.** The probability of hypothyroidism (gray) or hyperthyroidism (black), as defined by an increased or decreased TSH, respectively, based on a weighted genetic risk score (GRS) built using the 61 SNPs associated with TSH levels in the most recent GWAS by Teumer et al (19) is shown with respect to the percent of total risk alleles (x-axis). The gray histogram shows the distribution of the GRS in the study sample. Adapted from Teumer et al (19).

suggests that every person has a unique individual TSH and TH setpoint. Therefore, normalization of TSH and TH levels in thyroid disease patients after the initiation of treatment to levels within the reference ranges cannot guarantee the euthyroid status of that specific individual, as the achieved levels can still deviate from the individual setpoint. In addition, even TSH and TH levels within the reference range have been associated with an increased risk of cardiovascular events, including atherosclerotic cardiovascular disease and stroke (2, 3). Unfortunately, we seldom have TSH and TH levels before the onset of the thyroid disease, which could be used as a proxy of the individual setpoint. Mathematical models based on repeated measurements of TSH and TH levels of an individual on LT4 therapy have been proposed to estimate the individual HPT axis setpoint (102, 103), but this approach still requires clinical validation. While we currently cannot predict an individual's HPT axis setpoint, we do know that genetic factors are a major determinant of TSH and FT4 levels, next to individual and environmental factors such as age, gender, BMI, and iodine status (15). Future studies should therefore investigate if these factors can be used to predict the individual TSH and TH setpoint, which is a first step towards the personalized treatment of thyroid disease patients. This is important, as ~10% of hypothyroid patients on T4 treatment have persisting hypothyroid complaints (104, 105), which could be partially explained by the fact that their TSH and FT4 levels, despite being in the reference range, still deviate from their individual setpoint.

Moreover, knowing the individual TSH setpoint could be particularly useful in individuals with TSH levels close to (above/below) the upper limit of the reference range. This likely concerns a heterogeneous group, including individuals with normal thyroid function (ie, a setpoint at the extremes of the normal distribution) as well as individuals with (mild, early stage) thyroid disease. This is expected to be important as observational studies showed that subclinical hypothyroidism but also minor alterations in thyroid function are associated with adverse cardiovascular outcomes (2–4). Knowing the individual TSH setpoint could therefore further direct personalized treatment decisions. However, a better insight into the genetic determinants of thyroid function is still required in order to fully address this research question, as discussed below.

## Knowledge Gaps and Further Research Directions

While recent GWAS have led to an impressive increase in the identification of variants associated with thyroid function, these variants so far only explain 33% and 21% of the genetic variance in TSH and FT4 levels, respectively (19). This is still a major limitation for all clinical applications discussed above and identifying this “missing heritability” (106) will be a key task for this field.

### Further GWAS, WES, and WGS studies

The results of genetic association studies in complex traits and disorders, such as thyroid function and cardiovascular disease, have demonstrated that a large part of their genetic susceptibility is defined by multiple common variants with modest individual effect sizes. Therefore some of the “missing heritability” may be explained by common polymorphisms that contribute to the genetic susceptibility with even smaller effect sizes than those already identified in previous GWAS. For this, larger GWAS are needed. Moreover, while most of GWAS performed so far included mainly Caucasians (19, 22–28), future studies should also investigate the genetic basis of thyroid function in other ethnic groups. This is important since interethnic variations in allele frequencies may result in substantial differences in effect sizes and overall contribution for the identified variants across populations. Although requiring large sample sizes, gene–gene and gene–environment interactions, such as with iodine status, should also be investigated in these future studies, as these are potentially significant contributors to the genetic architecture of complex traits and disorders (107, 108).

While GWAS on thyroid function managed to identify multiple variants associated with TSH and FT4 levels, still little is known on the genetic factors determining FT3 levels, as they were not assessed in well-powered studies. Triiodothyronine (T3) is the active form of TH responsible for most of its metabolic effects (109). In 2010, a GWAS performed by Panicker et al in a cohort of 2014 female twins from the British population failed to identify any variants associated with FT3 levels at the genome-wide significant level (25). Most recently, another small (N = 1731) GWAS in the Croatian population identified the *EPH receptor B2 (EPHB2)* gene variant (rs67142165) as a new locus for FT3 levels (110). However, this finding requires confirmation in an independent study. Therefore, similar to TSH and FT4, well-powered GWAS meta-analyses are needed to effectively investigate the genetic determinants of FT3 levels.

Of note, there may be also rare variants conferring larger effects that can be identified in whole genome sequencing (WGS) or whole exome sequencing (WES) studies (106). The potential success of such studies is, for example, illustrated by a WGS study in 21 620 unrelated individuals of European ancestry, which showed that rare variants can be responsible for approximately 54% and 51% of heritability for height and BMI, respectively (111). While the first WGS study on thyroid function performed by Taylor et al managed to identify only two novel loci associated with TSH and TH levels (*B4GALT6* and *SYN2*) (34), further WES or WGS studies with larger sample size are expected to identify more rare variants that could explain a substantial proportion of the “missing heritability” (112).

### Epigenetic determinants of thyroid function and other omics in consortia

Epigenetic modifications such as DNA methylation, acetylation, phosphorylation, ubiquitination, and methylation of histones can regulate gene expression by alternations in DNA configuration. These nonpermanent changes are involved in cell proliferation and differentiation, but some of them can also be heritable or modified by environmental factors (113). Therefore, epigenetic modifications can be responsible for an important part of the “missing heritability” (114). While other fields in medicine have made significant progress in the understanding of the role of methylation (115, 116), its role in the regulation of thyroid function is still poorly understood. Therefore, further studies, including epigenome-wide association studies (EWAS), are warranted.

Finally, population-based studies employing other omics, such as transcriptomics, proteomics, and metabolomics, are outside the scope of this review, but they may also lead to new insights in thyroid physiology and pathophysiology, as recently discussed elsewhere (117).

### Functional studies

As mentioned before, an important part of the loci identified in GWAS on thyroid function has no known role yet in TH regulation. As illustrated by the *AADAT* and the *SLC17A4* examples (19), further in vitro studies are a key step to discover new players involved in the regulation of thyroid function and investigate their potential role in thyroid disease. Similarly, in vitro studies are also needed for the newly associated variants in known TH pathway genes, which will further increase our understanding of TH regulation.

## Conclusions

In recent years, GWAS have identified many novel genetic variants, which determine individual TSH and FT4 levels. These findings have not only led to the discovery of new genes that play a role in regulation of thyroid function, but have also paved the way for various other applications. Mendelian Randomization studies are expected to improve our understanding of the relationships between thyroid (dys)function and various adverse health outcomes. Furthermore, with the identified genetic variants, we can start exploring ways to use these in future clinical practice, including thyroid disease risk prediction and personalization of its treatment. However, as their discriminative power is expected to still be too limited to be used in clinical practice yet, future studies in large-scale consortia are needed to decipher the unexplained genetic variance in thyroid function.

## Acknowledgments

**Funding:** A.K. is supported by the Exchange in Endocrinology Expertise (3E) program of the European Union of Medical Specialists (UEMS), Section and Board of Endocrinology. M.M. is supported by research grants from the American Thyroid Association and European Thyroid Association, and an Erasmus University EUR fellowship grant.

## Additional Information

**Correspondence and Reprint Requests:** Marco Medici, MD, PhD, Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands. E-mail: [Marco.Medici@radboudumc.nl](mailto:Marco.Medici@radboudumc.nl).

**Disclosure Summary:** The authors have nothing to disclose.

## References

1. Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism. *Nat Rev Endocrinol*. 2018;**14**(5):301–316.
2. Bano A, Chaker L, Mattace-Raso FUS, et al. Thyroid function and the risk of atherosclerotic cardiovascular morbidity and mortality: The Rotterdam study. *Circ Res*. 2017;**121**(12):1392–1400.
3. Chaker L, Baumgartner C, den Elzen WP, et al.; Thyroid Studies Collaboration. Thyroid function within the reference range and the risk of stroke: An individual participant data analysis. *J Clin Endocrinol Metab*. 2016;**101**(11):4270–4282.
4. Chaker L, Heeringa J, Dehghan A, et al. Normal thyroid function and the risk of atrial fibrillation: The Rotterdam study. *J Clin Endocrinol Metab*. 2015;**100**(10):3718–3724.
5. Chaker L, Ligthart S, Korevaar TI, et al. Thyroid function and risk of type 2 diabetes: A population-based prospective cohort study. *BMC Med*. 2016;**14**(1):150.



6. Ruhla S, Weickert MO, Arafat AM, et al. A high normal TSH is associated with the metabolic syndrome. *Clin Endocrinol (Oxf)*. 2010;72(5):696–701.
7. Aubert CE, Floriani C, Bauer DC, et al.; Thyroid Studies Collaboration. Thyroid function tests in the reference range and fracture: Individual participant analysis of prospective cohorts. *J Clin Endocrinol Metab*. 2017;102(8):2719–2728.
8. Chaker L, Wolters FJ, Bos D, et al. Thyroid function and the risk of dementia: The Rotterdam study. *Neurology*. 2016;87(16):1688–1695.
9. Medici M, Direk N, Visser WE, et al. Thyroid function within the normal range and the risk of depression: A population-based cohort study. *J Clin Endocrinol Metab*. 2014;99(4):1213–1219.
10. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. *J Clin Endocrinol Metab*. 2006;91(11):4295–4301.
11. Haymart MR, Repplinger DJ, Levenson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. *J Clin Endocrinol Metab*. 2008;93(3):809–814.
12. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid*. 2016;26(1):1–133.
13. Inoue K, Tsujimoto T, Saito J, Sugiyama T. Association between serum thyrotropin levels and mortality among euthyroid adults in the United States. *Thyroid*. 2016;26(10):1457–1465.
14. Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations in serum T(4) and T(3) in normal subjects: A clue to the understanding of subclinical thyroid disease. *J Clin Endocrinol Metab*. 2002;87(3):1068–1072.
15. Chaker L, Korevaar TI, Medici M, et al. Thyroid function characteristics and determinants: The Rotterdam study. *Thyroid*. 2016;26(9):1195–1204.
16. Hansen PS, Brix TH, Sørensen TI, Kyvik KO, Hegedüs L. Major genetic influence on the regulation of the pituitary-thyroid axis: A study of healthy Danish twins. *J Clin Endocrinol Metab*. 2004;89(3):1181–1187.
17. Medici M, Visser WE, Visser TJ, Peeters RP. Genetic determination of the hypothalamic-pituitary-thyroid axis: Where do we stand? *Endocr Rev*. 2015;36(2):214–244.
18. Medici M, Visser TJ, Peeters RP. Genetics of thyroid function. *Best Pract Res Clin Endocrinol Metab*. 2017;31(2):129–142.
19. Teumer A, Chaker L, Groeneweg S, et al.; Lifelines Cohort Study. Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation. *Nat Commun*. 2018;9(1):4455.
20. Manolio TA. Genomewide association studies and assessment of the risk of disease. *The New England J of Med*. 2010;363(2):166–176.
21. Pe'er I, Yelensky R, Altshuler D, Daly MJ. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. *Genet Epidemiol*. 2008;32(4):381–385.
22. Arnaud-Lopez L, Usala G, Ceresini G, et al. Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function. *Am J Hum Genet*. 2008;82(6):1270–1280.
23. Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Discovery of common variants associated with low TSH levels and thyroid cancer risk. *Nat Genet*. 2012;44(3):319–322.
24. Porcu E, Medici M, Pistis G, et al. A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function. *PLoS Genet*. 2013;9(2):e1003266.
25. Panicker V, Wilson SG, Walsh JP, et al. A locus on chromosome 1p36 is associated with thyrotropin and thyroid function as identified by genome-wide association study. *Am J Hum Genet*. 2010;87(3):430–435.
26. Rawal R, Teumer A, Völzke H, et al. Meta-analysis of two genome-wide association studies identifies four genetic loci associated with thyroid function. *Hum Mol Genet*. 2012;21(14):3275–3282.
27. Malinowski JR, Denny JC, Bielinski SJ, et al. Genetic variants associated with serum thyroid stimulating hormone (TSH) levels in European Americans and African Americans from the eMERGE Network. *Plos One*. 2014;9(12):e111301.
28. Nielsen TR, Appel EV, Svendstrup M, et al. A genome-wide association study of thyroid stimulating hormone and free thyroxine in Danish children and adolescents. *PLOS One*. 2017;12(3):e0174204.
29. Kwak SH, Park YJ, Go MJ, et al. A genome-wide association study on thyroid function and anti-thyroid peroxidase antibodies in Koreans. *Hum Mol Genet*. 2014;23(16):4433–4442.
30. Zhan M, Chen G, Pan CM, et al.; China Consortium for Genetics of Autoimmune Thyroid Disease. Genome-wide association study identifies a novel susceptibility gene for serum TSH levels in Chinese populations. *Hum Mol Genet*. 2014;23(20):5505–5517.
31. Lowe JK, Maller JB, Pe'er I, et al. Genome-wide association studies in an isolated founder population from the Pacific Island of Kosrae. *Plos Genet*. 2009;5(2):e1000365.
32. Effraimidis G, Wiersinga WM. Mechanisms in endocrinology: Autoimmune thyroid disease: Old and new players. *Eur J Endocrinol*. 2014;170(6):R241–R252.
33. Płoski R, Szymański K, Bednarczuk T. The genetic basis of graves' disease. *Curr Genomics*. 2011;12(8):542–563.
34. Taylor PN, Porcu E, Chew S, et al.; UK0K Consortium. Whole-genome sequence-based analysis of thyroid function. *Nat Commun*. 2015;6:5681.
35. Hansen PS, van der Deure WM, Peeters RP, et al. The impact of a TSH receptor gene polymorphism on thyroid-related phenotypes in a healthy Danish twin population. *Clin Endocrinol (Oxf)*. 2007;66(6):827–832.
36. Peeters RP, van Toor H, Klootwijk W, et al. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. *J Clin Endocrinol Metab*. 2003;88(6):2880–2888.
37. Gudbjartsson DF, Helgason H, Gudjonsson SA, et al. Large-scale whole-genome sequencing of the Icelandic population. *Nat Genet*. 2015;47(5):435–444.
38. Roef GL, Rietzschel ER, De Meyer T, et al. Associations between single nucleotide polymorphisms in thyroid hormone transporter genes (MCT8, MCT10 and OATP1C1) and circulating thyroid hormones. *Clin Chim Acta*. 2013;425:227–232.
39. van der Deure WM, Friesema EC, de Jong FJ, et al. Organic anion transporter 1B1: an important factor in hepatic thyroid hormone and estrogen transport and metabolism. *Endocrinology*. 2008;149(9):4695–4701.
40. Panicker V, Cluett C, Shields B, et al. A common variation in deiodinase 1 gene DIO1 is associated with the relative levels of free thyroxine and triiodothyronine. *J Clin Endocrinol Metab*. 2008;93(8):3075–3081.
41. Medici M, van der Deure WM, Verbiest M, et al. A large-scale association analysis of 68 thyroid hormone pathway genes with serum TSH and FT4 levels. *Eur J Endocrinol*. 2011;164(5):781–788.
42. Yamada M, Mori M. Mechanisms related to the pathophysiology and management of central hypothyroidism. *Nat Clin Pract Endocrinol Metab*. 2008;4(12):683–694.
43. Lichti-Kaiser K, ZeRuth G, Kang HS, Vasanth S, Jetten AM. Glimilar proteins: Their mechanisms of action, physiological functions, and roles in disease. *Vitam Horm*. 2012;88:141–171.
44. Kang HS, Kumar D, Liao G, et al. GLIS3 is indispensable for TSH/TSHR-dependent thyroid hormone biosynthesis and follicular cell proliferation. *J Clin Invest*. 2017;127(12):4326–4337.

45. Rurale G, Persani L, Marelli F. GLIS3 and thyroid: A pleiotropic candidate gene for congenital hypothyroidism. *Front Endocrinol (Lausanne)*. 2018;9:730.
46. Klein M, Catargi B. VEGF in physiological process and thyroid disease. *Ann Endocrinol (Paris)*. 2007;68(6):438–448.
47. Wang JF, Milosveski V, Schramek C, Fong GH, Becks GP, Hill DJ. Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. *J Endocrinol*. 1998;157(1):5–12.
48. Revest JM, Spencer-Dene B, Kerr K, De Moerlooze L, Rosewell I, Dickson C. Fibroblast growth factor receptor 2-IIIb acts upstream of Shh and Fgf4 and is required for limb bud maintenance but not for the induction of Fgf8, Fgf10, Msx1, or Bmp4. *Dev Biol*. 2001;231(1):47–62.
49. Teumer A, Rawal R, Homuth G, et al. Genome-wide association study identifies four genetic loci associated with thyroid volume and goiter risk. *Am J Hum Genet*. 2011;88(5):664–673.
50. Hansen PS, Brix TH, Bennedbaek FN, Bonnema SJ, Kyvik KO, Hegedüs L. Genetic and environmental causes of individual differences in thyroid size: A study of healthy Danish twins. *J Clin Endocrinol Metab*. 2004;89(5):2071–2077.
51. Gómez JM, Maravall FJ, Gómez N, Gumà A, Casamitjana R, Soler J. Pituitary-thyroid axis, thyroid volume and leptin in healthy adults. *Horm Metab Res*. 2002;34(2):67–71.
52. Barrère X, Valeix P, Preziosi P, et al. Determinants of thyroid volume in healthy French adults participating in the SU.VI.MAX cohort. *Clin Endocrinol (Oxf)*. 2000;52(3):273–278.
53. Johner SA, Thamm M, Stehle P, et al. Interrelations between thyrotropin levels and iodine status in thyroid-healthy children. *Thyroid*. 2014;24(7):1071–1079.
54. Boas M, Hegedüs L, Feldt-Rasmussen U, Skakkebaek NE, Hilsted L, Main KM. Association of thyroid gland volume, serum insulin-like growth factor-I, and anthropometric variables in euthyroid prepubertal children. *J Clin Endocrinol Metab*. 2009;94(10):4031–4035.
55. Goh DL, Patel A, Thomas GH, et al. Characterization of the human gene encoding alpha-amino adipate aminotransferase (AADAT). *Mol Genet Metab*. 2002;76(3):172–180.
56. Zhu W, Deng Y, Zhou X. Multiple membrane transporters and some immune regulatory genes are major genetic factors to Gout. *Open Rheumatol J*. 2018;12:94–113.
57. Togawa N, Miyaji T, Izawa S, Omote H, Moriyama Y. A Na<sup>+</sup>-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. *Am J Physiol Cell Physiol*. 2012;302(11):C1652–C1660.
58. Hernandez A, Martinez ME, Fiering S, Galton VA, St Germain D. Type 3 deiodinase is critical for the maturation and function of the thyroid axis. *J Clin Invest*. 2006;116(2):476–484.
59. Hernandez A, Martinez ME, Liao XH, et al. Type 3 deiodinase deficiency results in functional abnormalities at multiple levels of the thyroid axis. *Endocrinology*. 2007;148(12):5680–5687.
60. Hernandez A, Martinez ME, Croteau W, St Germain DL. Complex organization and structure of sense and antisense transcripts expressed from the DIO3 gene imprinted locus. *Genomics*. 2004;83(3):413–424.
61. Kester MH, Kuiper GG, Versteeg R, Visser TJ. Regulation of type III iodothyronine deiodinase expression in human cell lines. *Endocrinology*. 2006;147(12):5845–5854.
62. Hernandez A, Stohn JP. The Type 3 deiodinase: Epigenetic control of brain thyroid hormone action and neurological function. *Int J Mol Sci*. 2018;19(6):1804.
63. Deng WB, Liang XH, Liu JL, Yang ZM. Regulation and function of deiodinases during decidualization in female mice. *Endocrinol*. 2014;155(7):2704–2717.
64. Coppotelli G, Summers A, Chidakel A, Ross JM, Celi FS. Functional characterization of the 258 A/G (D2-ORFα-Gly3Asp) human type-2 deiodinase polymorphism: A naturally occurring variant increases the enzymatic activity by removing a putative repressor site in the 5' UTR of the gene. *Thyroid*. 2006;16(7):625–632.
65. Peeters RP, van den Beld AW, Attalki H, et al. A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. *Am J Physiol Endocrinol Metab*. 2005;289(1):E75–E81.
66. Peeters RP, van der Deure WM, Visser TJ. Genetic variation in thyroid hormone pathway genes; polymorphisms in the TSH receptor and the iodothyronine deiodinases. *Eur J Endocrinol*. 2006;155(5):655–662.
67. de Jong FJ, Peeters RP, den Heijer T, et al. The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe. *J Clin Endocrinol Metab*. 2007;92(2):636–640.
68. Canani LH, Capp C, Dora JM, et al. The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. *J Clin Endocrinol Metab*. 2005;90(6):3472–3478.
69. Castagna MG, Dentice M, Cantara S, et al. DIO2 Thr92Ala reduces deiodinase-2 activity and serum-T3 levels in thyroid-deficient patients. *J Clin Endocrinol Metab*. 2017;102(5):1623–1630.
70. McAninch EA, Jo S, Preite NZ, et al. Prevalent polymorphism in thyroid hormone-activating enzyme leaves a genetic fingerprint that underlies associated clinical syndromes. *J Clin Endocrinol Metab*. 2015;100(3):920–933.
71. Appelhof BC, Peeters RP, Wiersinga WM, et al. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3'-triiodothyronine therapy. *J Clin Endocrinol Metab*. 2005;90(11):6296–6299.
72. Wouters HJ, van Loon HC, van der Klauw MM, et al. No effect of the Thr92Ala polymorphism of deiodinase-2 on thyroid hormone parameters, health-related quality of life, and cognitive functioning in a large population-based cohort Study. *Thyroid*. 2017;27(2):147–155.
73. Tam V, Patel N, Turcotte M, Bossé Y, Paré G, Meyre D. Benefits and limitations of genome-wide association studies. *Nat Rev Genet*. 2019;20(8):467–484.
74. Chaker L, Cappola AR, Mooijjaart SP, Peeters RP. Clinical aspects of thyroid function during ageing. *Lancet Diabetes Endocrinol*. 2018;6(9):733–742.
75. Chaker L, Korevaar TIM, Rizopoulos D, et al. Defining optimal health range for thyroid function based on the risk of cardiovascular disease. *J Clin Endocrinol Metab*. 2017;102(8):2853–2861.
76. Grimes DA, Schulz KF. Bias and causal associations in observational research. *Lancet*. 2002;359(9302):248–252.
77. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. *Epidemiol*. 2017;28(1):30–42.
78. Zheng J, Baird D, Borges MC, et al. Recent developments in Mendelian randomization studies. *Curr Epidemiol Rep*. 2017;4(4):330–345.
79. Burgess S, Thompson SG; CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. *Int J Epidemiol*. 2011;40(3):755–764.
80. Glymour MM, Tchetgen Tchetgen EJ, Robins JM. Credible Mendelian randomization studies: Approaches for evaluating the instrumental variable assumptions. *Am J Epidemiol*. 2012;175(4):332–339.
81. Brion MJ, Shakhbuzov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. *Int J Epidemiol*. 2013;42(5):1497–1501.
82. Zhao JW, Schooling CM. Thyroid function and ischemic heart disease: a Mendelian randomization study. *Sci Rep*. 2017;7(1):8515.

83. Larsson SC, Allara E, Mason AM, Michaëlsson K, Burgess S. Thyroid function and dysfunction in relation to 16 cardiovascular diseases. *Circ Genom Precis Med*. 2019;12(3):e002468.
84. Bos MM, Smit RAJ, Trompet S, van Heemst D, Noordam R. Thyroid signaling, insulin resistance, and 2 diabetes mellitus: A Mendelian randomization study. *J Clin Endocrinol Metab*. 2017;102(6):1960–1970.
85. van Vliet NA, Noordam R, van Klinken JB, et al. Thyroid stimulating hormone and bone mineral density: Evidence from a two-sample Mendelian randomization study and a candidate gene association study. *J Bone Miner Res*. 2018;33(7):1318–1325.
86. Chen C, Xia F, Chen Y, et al. Association between thyroid-stimulating hormone and renal function: a Mendelian randomization study. *Kidney Blood Press Res*. 2018;43(4):1121–1130.
87. Ellervik C, Roselli C, Christophersen IE, et al. Assessment of the relationship between genetic determinants of thyroid function and atrial fibrillation: a Mendelian randomization study. *JAMA Cardiol*. 2019;4(2):144–152.
88. Salem JE, Shoemaker MB, Bastarache L, et al. Association of thyroid function genetic predictors with atrial fibrillation: a phenotype-wide association study and inverse-variance weighted average meta-analysis. *JAMA Cardiol*. 2019;4(2):136–143.
89. Medici M, Peeters RP, Teumer A, Taylor P. The importance of high-quality mendelian randomisation studies for clinical thyroidology. *Lancet Diabetes Endocrinol*. 2019;7(9):665–667.
90. Medici M, Porcu E, Pistis G, et al. Identification of novel genetic Loci associated with thyroid peroxidase antibodies and clinical thyroid disease. *Plos Genet*. 2014;10(2):e1004123.
91. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. *Endocr Rev*. 2002;23(1):38–89.
92. Maino F, Cantara S, Forleo R, Pilli T, Castagna MG. Clinical significance of type 2 iodothyronine deiodinase polymorphism. *Expert Rev Endocrinol Metab*. 2018;13(5):273–277.
93. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. *J Clin Endocrinol Metab*. 2009;94(5):1623–1629.
94. Saravanan P, Simmons DJ, Greenwood R, Peters TJ, Dayan CM. Partial substitution of thyroxine (T4) with tri-iodothyronine in patients on T4 replacement therapy: Results of a large community-based randomized controlled trial. *J Clin Endocrinol Metab*. 2005;90(2):805–812.
95. VanderZee KI, Sanderman R, Heyink JW, de Haes H. Psychometric qualities of the RAND 36-Item Health Survey 1.0: a multidimensional measure of general health status. *Int J Behav Med*. 1996;3(2):104–122.
96. Carlé A, Faber J, Steffensen R, Laurberg P, Nygaard B. Hypothyroid patients encoding combined MCT10 and DIO2 gene polymorphisms may prefer L-T3 + L-T4 combination treatment - data using a blind, randomized, clinical study. *Eur Thyroid J*. 2017;6(3):143–151.
97. Khera AV, Emdin CA, Drake I, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. *N Engl J Med*. 2016;375(24):2349–2358.
98. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nat Genet*. 2018;50(9):1219–1224.
99. Knowles JW, Ashley EA. Cardiovascular disease: The rise of the genetic risk score. *Plos Med*. 2018;15(3):e1002546.
100. Stower H. Restoring sight with native cell reprogramming. *Nat Med*. 2018;24(9):1303.
101. Schultheiss UT, Teumer A, Medici M, et al. A genetic risk score for thyroid peroxidase antibodies associates with clinical thyroid disease in community-based populations. *J Clin Endocrinol Metab*. 2015;100(5):E799–E807.
102. Goede SL, Leow MK, Smit JW, Dietrich JW. A novel minimal mathematical model of the hypothalamus-pituitary-thyroid axis validated for individualized clinical applications. *Math Biosci*. 2014;249:1–7.
103. Meng F, Li E, Yen PM, Leow MKS. Hyperthyroidism in the personalized medicine era: The rise of mathematical optimization. *J R Soc Interface*. 2019;16(155):20190083.
104. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. *Arch Intern Med*. 2000;160(4):526–534.
105. Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP. 2012 ETA guidelines: The use of L-T4 + L-T3 in the treatment of hypothyroidism. *Eur Thyroid J*. 2012;1(2):55–71.
106. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. *Nature*. 2009;461(7265):747–753.
107. Aschard H, Lutz S, Maus B, et al. Challenges and opportunities in genome-wide environmental interaction (GWEI) studies. *Hum Genet*. 2012;131(10):1591–1613.
108. Ritchie MD, Van Steen K. The search for gene-gene interactions in genome-wide association studies: Challenges in abundance of methods, practical considerations, and biological interpretation. *Ann Transl Med*. 2018;6(8):157.
109. Yen PM. Physiological and molecular basis of thyroid hormone action. *Physiol Rev*. 2001;81(3):1097–1142.
110. Popović M, Matana A, Torlak V, et al. Genome-wide meta-analysis identifies novel loci associated with free triiodothyronine and thyroid-stimulating hormone. *J Endocrinol Invest*. 2019;42(10):1171–1180.
111. Wainschtein P, Jain DP, Yengo L, et al. Recovery of trait heritability from whole genome sequence data. *bioRxiv*. 2019. doi: 10.1101/588020.
112. Zuk O, Schaffner SF, Samocha K, et al. Searching for missing heritability: Designing rare variant association studies. *Proc Natl Acad Sci U S A*. 2014;111(4):E455–E464.
113. Feil R, Fraga MF. Epigenetics and the environment: Emerging patterns and implications. *Nat Rev Genet*. 2012;13(2):97–109.
114. Trerotola M, Relli V, Simeone P, Alberti S. Epigenetic inheritance and the missing heritability. *Hum Genomics*. 2015;9:17.
115. Fernández-Sanlés A, Sayols-Baixeras S, Subirana I, Degano IR, Elosua R. Association between DNA methylation and coronary heart disease or other atherosclerotic events: A systematic review. *Atherosclerosis*. 2017;263:325–333.
116. Chen D, Meng L, Pei F, Zheng Y, Leng J. A review of DNA methylation in depression. *J Clin Neurosci*. 2017;43:39–46.
117. Pietzner M, Kacprowski T, Friedrich N. Empowering thyroid hormone research in human subjects using OMICS technologies. *J Endocrinol*. 2018;238(1):R13–R29.